ABSTRACT
This study aimed to investigate the effect and mechanisms of Ephedra Herb (EH) extract on adriamycin-induced nephrotic syndrome (NS), providing an experimental basis for the clinical treatment of NS. Hematoxylin and eosin staining, creatinine, urea nitrogen, and kidn injury molecule-1 were used to evaluate the activities of EH extract on renal function. The levels of inflammatory factors and oxidative stress were detected by kits. The levels of reactive oxygen species, immune cells, and apoptosis were measured by flow cytometry. A network pharmacological approach was used to predict the potential targets and mechanisms of EH extract in the treatment of NS. The protein levels of apoptosis-related proteins and CAMKK2, p-CAMKK2, AMPK, p-AMPK, mTOR and p-mTOR in the kidneys were detected by Western blot. The effective material basis of EH extract was screened by MTT assay. The AMPK pathway inhibitor (compound C, CC) was added to investigate the effect of the potent material basis on adriamycin-induced cell injury. EH extract significantly improved renal injury and relieve inflammation, oxidative stress, and apoptosis in rats. Network pharmacology and Western blot results showed that the effect of EH extract on NS may be associated with the CAMKK2/AMPK/mTOR signaling pathway. Moreover, methylephedrine significantly ameliorated adriamycin-induced NRK-52e cell injury. Methylephedrine also significantly improved the phosphorylation of AMPK and mTOR, which were blocked by CC. In sum, EH extract may ameliorate renal injury via the CAMKK2/AMPK/mTOR signaling pathway. Moreover, methylephedrine may be one of the material bases of EH extract.
Subject(s)
Rats , Animals , Doxorubicin/adverse effects , Nephrotic Syndrome , AMP-Activated Protein Kinases/metabolism , Signal Transduction , TOR Serine-Threonine Kinases/metabolism , ApoptosisABSTRACT
Based on the association rules,the relation between syndromes and immunofluorescence staining test results (renal pathological lest) were analyzed among 201 cases with IgA nephropathy to provide evidence for treatment and prognosis of this disease.
ABSTRACT
Objective To observe clinical effect of treating stomachache of spleen-stomach deficiency syndrome with modified Buzhongyiqi decoction. Methods 29 stomachache patients of spleen-stomach deficiency syndrome were randomly recurited into a control group and a treatment group. The control group was treated with western medicine, and the treatment group was treated with modified Buzhongyiqi decoction. The clinical effect was observed in both groups. Results The clinical effect in the treatment group was significantly higher than that of the control group (P<0.05). Condusion The treatment of stomachache patients with spleen-stomach deficiency syndrome with modified Buzhongyiqi decoction was more effective than western medicine.